Mohammad Chisti, MD
Hematology & Oncology · Troy, MINPI 1598911448
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $132,360 of the $179,687 with a category attached, or 73.7%. Lilly USA, LLC accounts for 74.4% of it on its own, with 35 other manufacturers making up the rest. Reporting peaked in 2019 at $53,694 and has fallen 93.1% since, to $3,683 in 2025. Among hematology & oncology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 246 payments — averaging $730.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$134K
- E.r. Squibb & Sons, L.L.C.$18K
- AstraZeneca$7K
- Incyte Corporation$6K
- Immunogen, Inc.$6K
- Deciphera Pharmaceuticals Inc.$4K
- plus $5K from 30 others
What the payments were for
- Consulting fees$28,32816%
- Speaking & faculty fees$132,36074%
- Travel & lodging$13,8438%
- Food & beverage$4,5843%
- Education$5720%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 161 | $133,646 |
| E.r. Squibb & Sons, L.L.C. | 14 | $18,444 |
| AstraZeneca | 13 | $6,561 |
| Incyte Corporation | 12 | $6,074 |
| Immunogen, Inc. | 4 | $5,949 |
| Deciphera Pharmaceuticals Inc. | 6 | $4,198 |
| AbbVie | 1 | $1,800 |
| Bayer | 1 | $1,370 |
| Boehringer Ingelheim | 1 | $650 |
| Regeneron Healthcare Solutions, Inc. | 1 | $125 |
| Tempus AI, Inc | 1 | $113 |
| Exelixis Inc. | 1 | $107 |
| Medtronic | 1 | $51 |
| Sanofi | 2 | $44 |
| Novartis | 2 | $39 |
| Endomagnetics Ltd | 1 | $38 |
| GSK | 2 | $38 |
| Astellas Pharma US Inc | 2 | $36 |
| Gilead | 2 | $34 |
| Emmaus Medical, Inc. | 1 | $33 |
| Jazz Pharmaceuticals Inc. | 1 | $32 |
| Pfizer | 2 | $29 |
| Beigene USA, Inc. | 1 | $26 |
| Bristol Myers Squibb | 1 | $23 |
| Amgen | 1 | $23 |
| Puma Biotechnology, Inc. | 1 | $23 |
| Genentech USA, Inc. | 1 | $22 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $21 |
| Azurity Pharmaceuticals, Inc. | 1 | $21 |
| Recordati_rare_diseases_inc. | 1 | $18 |
| Blueprint Medicines Corporation | 1 | $18 |
| Mirati Therapeutics, Inc. | 1 | $18 |
| Merck | 1 | $18 |
| Acrotech Biopharma Inc. | 1 | $17 |
| Myriad Genetic Laboratories, Inc. | 1 | $16 |
| Sobi, Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$179,687 in reported general payments places this provider in the 95th percentile of 282 hematology & oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 43 | $858,058 |
| BrukinsaZanubrutinib | 67 | $664,490 |
| JakafiRuxolitinib Phosphate | 43 | $657,749 |
| KisqaliRibociclib Succinate | 27 | $385,395 |
| IbrancePalbociclib | 23 | $358,989 |
| CabometyxCabozantinib S-Malate | 13 | $320,615 |
| ImbruvicaIbrutinib | 16 | $264,138 |
| TasignaNilotinib Hcl | 12 | $246,511 |
| Lenalidomide | 18 | $242,183 |
| EliquisApixaban | 192 | $211,399 |
| VenclextaVenetoclax | 25 | $197,529 |
| NubeqaDarolutamide | 12 | $164,738 |
| Abiraterone Acetate | 27 | $104,041 |
| XareltoRivaroxaban | 31 | $25,531 |
| Anastrozole | 237 | $9,226 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $23 | $858,05843 claims |
| Beigene USA, Inc.Brukinsa | $26 | $664,49067 claims |
| Incyte CorporationJakafi | $6,074 | $657,74943 claims |
| NovartisKisqali, Tasigna | $39 | $631,90539 claims |
| PfizerIbrance, Eliquis | $29 | $570,388215 claims |
| Exelixis Inc.Cabometyx | $107 | $320,61513 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $21 | $264,13816 claims |
| AbbVieVenclexta | $1,800 | $197,52925 claims |
| BayerNubeqa | $1,370 | $164,73812 claims |
| Lilly USA, LLCOlanzapine | $133,646 | $16849 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 282 hematology & oncology providers in Michigan.
Other hematology & oncology in Troy
- Mitchell FolbeTroy$30K
- Faisal MusaDearborn$976K
- Mohammed Al HallakDetroit$644K
- Daniel LebovicGrosse Pointe Woods$352K
- Sreenivasa ChandanaGrand Rapids$305K
- Gordon SrkalovicLansing$167K
- Jeffrey ZonderDetroit$88K
- Madan AroraFlint$84K
- Hadeel AssadDetroit$80K
- Andrew MuskovitzSouthfield$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.